How serious is FDA warning about revolutionary blood-cancer

Dana-Farber Cancer Institute researcher details promise, peril of CAR T-cell therapy, which enlists body’s immune system to fight disease.

Carvykti CAR-T gets warning label - STAT

Susan B. Nichols en LinkedIn: FDA to back accelerated approval pathway for gene therapies (NASDAQ:SRPT)

Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients with Low-Risk DCIS - Be part of the knowledge - ReachMD

DDC, Free Full-Text

Taking Stock of CAR T-Cell Therapy

FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a 'ticking time bomb', Health

News and Opinions - World Stem Cell Summit

Mark Flower on LinkedIn: FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with…

At $475,000, is Novartis' Kymriah a bargain—or another example of skyrocketing prices?